Compare Hewlett Packard Enterprise Co (HPE) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Medpace Holdings Inc — how do they compare? Hewlett Packard Enterprise Co trades at $73.13 (market cap $94.25B), while Medpace Holdings Inc trades at $617.62 (market cap $16.82B). The key difference: Hewlett Packard Enterprise Co is far larger — about 5.6× Medpace Holdings Inc's market cap, and Hewlett Packard Enterprise Co pays a 0.8% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and Medpace Holdings Inc for 14 Days on average.
| HPE | MEDP | |
|---|---|---|
Market Cap | $94.25B | $16.82B |
Volume | 16,060,854 | 223,093 |
Sector | Technology | Health |
52-Week High | $72.12 | $630.19 |
52-Week Low | $20.01 | $393.42 |
Typical Hold Time | 33 Days | 14 Days |
Enterprise Value | $108.28B | $16.44B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE trades at $71.75, near its all-time high, with strong momentum driven by AI infrastructure demand. The stock has gained over 160% year-over-year and recently received a bullish upgrade from Daiwa. Recent earnings beats and a $1.2 billion AI server order from Vultr highlight operational strength. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals reveal robust revenue growth projections to $41.9 billion in 2026.
Outlook remains positive with AI-driven growth catalysts, though valuation multiples appear elevated. Key risks include execution on Juniper integration and competitive pressures. Analyst consensus leans neutral with a $70.35 price target, suggesting limited near-term upside from current levels despite strong business momentum.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
